Open Nav

Please submit your session questions in advance at

InCarda Therapeutics

InCarda Therapeutics is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The lead product under development, InRhythm, is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. The company has raised over $50M and is currently conducting a Phase 2 trial to treat acute episodes of AF in Europe. If approved, InRhythm will be the only treatment available for patients to treat and quickly resolve their episodes of atrial fibrillation anytime, anywhere they happen to be.

  • Date:Monday, February 11
  • Time:2:45 PM - 3:00 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23370
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Company update for potential investors and partners
  • Company Website:
  • Company HQ City:Newark
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$50M
  • Size of Last Investment Round:$42M
  • Previous and Current Investors:Morningside, Sofinnova, HealthCap, Deerfield
  • CEO/Top Company Official:Grace E. Colon
  • Year Founded:2009
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development:InRhythm (inhaled flecainide for PAF)
  • Development Phase of Primary Product:Phase II
Grace Colón
InCarda Therapeutics